Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4701-4710 Newer>

The Motley Fool March 31, 2008 Brian Lawler	SGX Down for the Count? The pharmaceutical's lead drug fares poorly in clinical testing.
The Motley Fool March 31, 2008 Brian Lawler	GPC Recaps a Tough Year Development-stage drugmaker GPC Biotech releases its year-end financial results after a 2007 in which the FDA depth-charged its lead drug.
The Motley Fool March 31, 2008 Brian Lawler	A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds.
The Motley Fool March 31, 2008 Brian Orelli	No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating.
The Motley Fool March 31, 2008 Rich Duprey	Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment.
The Motley Fool March 31, 2008 Brian Orelli	Collateral Damage From an FDA Warning BioMimetic gets hit hard by a warning about a J&J drug.
The Motley Fool March 31, 2008 Rich Duprey	Foolish Forecast: Immucor's Draining Acquisition In advance of earnings, analysts expect blood-tester Immucor to continue to grow sales and profits, in spite of short-term expenses.
Chemistry World April 2008 Derek Lowe	Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain.
The Motley Fool March 28, 2008 Brian Lawler	Is the Dollar Depressing Drug Companies? The falling dollar means different things to big pharma here and in Europe.
The Motley Fool March 28, 2008 Brian Lawler	Vertex Tantalizes Us With Very Early Data Vertex announces positive early-stage data for a cystic fibrosis drug.
<Older 4701-4710 Newer> Return to current articles.